awmsg logo



rufinamide (Inovelon®)


Reference No. 991

Publication date:
26/06/2019


Appraisal information

rufinamide (Inovelon®) 40 mg/ml oral suspension


Company: Eisai Ltd
BNF category: Central nervous system
NMG meeting date: 08/05/2019
AWMSG meeting date: 19/06/2019
   
   
Submission Type: Limited Submission
Status: Recommended with restrictions
Advice No: 0919
Ratification by Welsh Government: 25/06/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Rufinamide (Inovelon®) is recommended as an option for restricted use within NHS Wales. Rufinamide (Inovelon®) is licensed as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 1 years of age and older. Rufinamide (Inovelon®) is restricted for use where other adjunctive treatments have proved sub-optimal or have not been tolerated. Rufinamide (Inovelon®) is not recommended for use within NHS Wales outside of this subpopulation.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download